Search Results - "McKenney, Mary"

CLAMP and Zelda function together to promote Drosophila zygotic genome activation by Duan, Jingyue, Rieder, Leila, Colonnetta, Megan M, Huang, Annie, Mckenney, Mary, Watters, Scott, Deshpande, Girish, Jordan, William, Fawzi, Nicolas, Larschan, Erica

“…During the essential and conserved process of zygotic genome activation (ZGA), chromatin accessibility must increase to promote transcription. Drosophila is a…”
Get full text

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma by Richardson, Paul G., Blood, Emily, Mitsiades, Constantine S., Jagannath, Sundar, Zeldenrust, Steven R., Alsina, Melissa, Schlossman, Robert L., Rajkumar, S. Vincent, Desikan, K. Raman, Hideshima, Teru, Munshi, Nikhil C., Kelly-Colson, Kathleen, Doss, Deborah, McKenney, Mary L., Gorelik, Svetlana, Warren, Diane, Freeman, Andrea, Rich, Rebecca, Wu, Anfang, Olesnyckyj, Marta, Wride, Kenton, Dalton, William S., Zeldis, Jerome, Knight, Robert, Weller, Edie, Anderson, Kenneth C.

“…This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were…”
Get full text

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma by RICHARDSON, Paul G, WELLER, Edie, WARREN, Diane L, LUNDE, Laura E, MCKENNEY, Mary, DELANEY, Carol, MITSIADES, Constantine S, HIDESHIMA, Teru, DALTON, William, KNIGHT, Robert, ESSELTINE, Dixie-Lee, ANDERSON, Kenneth C, JAGANNATH, Sundar, AVIGAN, David E, ALSINA, Melissa, SCHLOSSMAN, Robert L, MAZUMDER, Amitabha, MUNSHI, Nikhil C, GHOBRIAL, Irene M, DOSS, Deborah

“…Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to…”
Get full text

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease by Richardson, Paul G, Laubach, Jacob, Mitsiades, Constantine, Schlossman, Robert L, Doss, Deborah, Colson, Kathleen, McKenney, Mary L, Noonan, Kimberly, Warren, Diane L, Ghobrial, Irene M, Munshi, Nikhil C, Anderson, Kenneth

“…Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although…”
Get more information

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, Anderson, Kenneth C.

“…In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of…”
Get full text

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma by Streeter, Shawn O., Nadeem, Omar, Richardson, Paul G., Laubach, Jacob P., Mo, Clifton C., Noonan, Kimberly, McKenney, Mary, Flaherty, Tina, Dalton, Virginia, Aktas-Samur, Anil, Leblebjian, Houry

“…Introduction Lenalidomide, bortezomib, and dexamethasone (RVD) is a standard first-line regimen for patients with newly diagnosed multiple myeloma and is…”
Get full text

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma by Nadeem, Omar, Redd, Robert A., Barth, Peter, Mo, Clifton C, Laubach, Jacob P., Bianchi, Giada, Bayliss, Trevor J., Sanchorawala, Vaishali, Shune, Leyla, Distaso, Alexandra, Dalton, Virginia, McKenney, Mary, Patches, Sarah, Hou, Isabella, Issokson, Lindsay, Barrell, Anna, Masone, Kelly, Sperling, Adam S., Munshi, Nikhil C., Ghobrial, Irene M., Anderson, Kenneth C., Richardson, Paul G.

“…Introduction: Ixazomib is an oral proteasome inhibitor (PI) that is currently approved to be administered once weekly in combination with lenalidomide (LEN)…”
Get full text

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts by Nadeem, Omar, Mo, Clifton C, Laubach, Jacob P., Bianchi, Giada, Redd, Robert, Barth, Peter, Bayliss, Trevor J., Sanchorawala, Vaishali, Shune, Leyla, Distaso, Alexandra, Dalton, Virginia, Sperling, Adam S, Amweg, Laura, McKenney, Mary, Colson, Kathleen, Millard, Ella L, Hou, Isabella, Savell, Alexandra, Masone, Kelly, Munshi, Nikhil C., Ghobrial, Irene M., Anderson, Kenneth, Richardson, Paul G.

“…Introduction: Treatment of relapsed and refractory multiple myeloma (RRMM) continues to evolve as most patients are lenalidomide (LEN) refractory at the time…”
Get full text

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma by Richardson, Paul G., Schlossman, Robert L., Weller, Edie, Hideshima, Teru, Mitsiades, Constantine, Davies, Faith, LeBlanc, Richard, Catley, Laurence P., Doss, Deborah, Kelly, Kathleen, McKenney, Mary, Mechlowicz, Julie, Freeman, Andrea, Deocampo, Reggie, Rich, Rebecca, Ryoo, Joan J., Chauhan, Dharminder, Balinski, Kathe, Zeldis, Jerome, Anderson, Kenneth C.

“…Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro…”
Get full text

Sensitivity of evapotranspiration in a wheat field, a forest, and a grassland to changes in climate and direct effects of carbon dioxide by MARTIN, P

“…Penman-Monteith models of evapotranspiration for a wheat field in Nebraska, a forest in Tennessee, and a grassland in Kansas were developed based on…”
Get full text

Paper 1. the mink methodology: background and baseline by Rosenberg, Norman J, Crosson, Pierre R, Frederick, Kenneth D, Bowes, Michael D

“…A four step methodology, termed MINK, has been developed for study of the regional impacts of climate change and the possible responses thereto. Impacts of the…”
Get full text

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib by Richardson, Paul G., Laubach, Jacob P., Schlossman, Robert L., Ghobrial, Irene M., Redman, Katherine C., Mckenney, Mary, Warren, Diane, Noonan, Kimberly, Lunde, Laura, Doss, Deborah, Colson, Kathleen, Hideshima, Teru, Mitsiades, Constantine, Munshi, Nikhil C., Anderson, Kenneth C.

“…We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by…”
Get full text

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up by Richardson, Paul G, Jagannath, Sundar, Jakubowiak, Andrzej J, Lonial, Sagar, Raje, Noopur, Alsina, Melissa, Ghobrial, Irene, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Colson, Kathleen, McKenney, Mary L, Lunde, Laura E, Feather, John, Hideshima, Teru, Knight, Robert D, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Anderson, Kenneth C.

“…Abstract 3049 Single-agent bortezomib (btz) and lenalidomide (len)-dexamethasone (dex) are associated with higher rates of response and improved survival vs…”
Get full text

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study by Richardson, Paul, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur, Alsina, Melissa, Ghobrial, Irene, Mazumder, Amitabha, Munshi, Nikhil C, Vesole, David H, Colson, Kathleen, McKenney, Mary L, Lunde, Laura, Kennedy, Sarah, Kosakowski, Kara, Mitsiades, Constantine, Hideshima, Teru, Knight, Robert D, Esseltine, Dixie-Lee, Anderson, Kenneth C

“…Background: Bortezomib (VELCADE®, Bz) is approved for the treatment of multiple myeloma (MM). Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is…”
Get full text

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study by Richardson, Paul, Jagannath, Sundar, Raje, Noopur, Jakubowiak, Andrzej, Lonial, Sagar, Ghobrial, Irene, Schlossman, Robert, Mazumder, Amitabha, Munshi, Nikhil, Colson, Kathleen, McKenney, Mary, Farrell, Melissa, Lunde, Laura, Giove, Lawrence, Kaster, Sarah, Mitsiades, Constantine, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth

“…Background: Single-agent bortezomib (VELCADE®, Vel) and lenalidomide (Revlimid®, Rev) plus dexamethasone (Dex) are approved for relapsed MM patients (pts)…”
Get full text

Triplet sensitization and exciplex quenching of the photochemical reaction between phenanthrene and dimethyl fumarate by Creed, David, Caldwell, Richard A, Ulrich, Mary McKenney

Get full text

Paper 2. agricultural impacts of and responses to climate change in the Missouri-Iowa-Nebraska-Kansas (MINK) region by Easterling, William E, Crosson, Pierre R, Rosenberg, Norman J, Katz, Laura A

“…The climate of the 1930s was used as an analog of the climate that might occur in Missouri, Iowa, Nebraska and Kansas (the MINK region) as a consequence of…”
Get full text

Investigating the Basis of tRNA Editing and Modification Enzyme Coactivation in Trypanosoma brucei by McKenney, Katherine Mary

“…In all domains of life, transfer RNAs (tRNAs) undergo many post-transcriptional modifications and editing events that fine-tune their structural and functional…”
Get full text

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Commentary by LONIAL, Sagar, RICHARDSON, Paul G, HIDESHIMA, Teru, MUNSHI, Nikhil C, KELLY-COLSON, Kathleen, DOSS, Deborah, MCKENNEY, Mary L, GORELIK, Svetlana, WARREN, Diane, FREEMAN, Andrea, RICH, Rebecca, ANFANG WU, BLOOD, Emily, OLESNYCKYJ, Marta, WRIDE, Kenton, DALTON, William S, ZELDIS, Jerome, KNIGHT, Robert, WELLER, Edie, ANDERSON, Kenneth C, MITSIADES, Constantine S, JAGANNATH, Sundar, ZELDENRUST, Steven R, ALSINA, Melissa, SCHLOSSMAN, Robert L, RAJKUMAR, S. Vincent, RAMAN DESIKAN, K

Get full text

Agricultural impacts of and responses to climate change in the Missouri-Iowa-Nebraska-Kansas (Mink) region by Easterling, W.E. III (Nebraska Univ., Lincoln, NE (USA). Dept. of Agricultural Meteorology), Crosson, P.R, Rosenberg, N.J, McKenney, M.S, Katz, L.A, Lemon, K.M

“…As part of the MINK (Missouri-Iowa-Nebraska-Kansas) study, crop production was simulated for a set of representative farms across the MINK region under the…”
Get full text